Vaporized Cannabis Administration and Co-Administration of Alcohol on Impairment
The Impact of Vaporized Cannabis Administration and Co-Administration of Alcohol on Impairment
Johns Hopkins University
90 participants
Sep 26, 2024
INTERVENTIONAL
Conditions
Summary
This human laboratory study will use cognitive, behavioral, and subjective measures to characterize impairment associated with co-use of alcohol and vaporized cannabis. Participants (n=32) will complete 7 double-blind, double-dummy outpatient sessions in randomized order. In each session, participants will self-administer placebo (0 mg THC) or active vaporized cannabis (5 or 25 mg THC, via a handheld vaporizer called the Mighty Medic) and a placebo drink (BAC 0.0%) or alcohol drink calculated to produce a breath alcohol concentration (BAC) of 0.05%. Participants will also complete a positive control session in which the participant administers placebo cannabis and alcohol at a target BAC of 0.08% (the legal threshold for driving impairment in most U.S. states).
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Cannabis will be vaporized using the Mighty Medic
Alcohol will be orally ingested via a flavored drink
Placebo cannabis (i.e., water vapor) will be vaporized using the Mighty Medic.
A non-alcoholic, placebo, flavored drink will be orally ingested.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06293040